- Home
- KFS vs TNXP Comparison
KFS vs TNXP Comparison
Compare KFS & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFS
- TNXP
- Stock Information
- Founded
- KFS 1989
- TNXP 2007
- Country
- KFS United States
- TNXP United States
- Employees
- KFS N/A
- TNXP N/A
- Industry
- KFS Property-Casualty Insurers
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- KFS Finance
- TNXP Health Care
- Exchange
- KFS Nasdaq
- TNXP Nasdaq
- Market Cap
- KFS 218.4M
- TNXP 207.5M
- IPO Year
- KFS 1996
- TNXP N/A
- Fundamental
- Price
- KFS $12.86
- TNXP $39.78
- Analyst Decision
- KFS
- TNXP Strong Buy
- Analyst Count
- KFS 0
- TNXP 2
- Target Price
- KFS N/A
- TNXP $585.00
- AVG Volume (30 Days)
- KFS 56.3K
- TNXP 1.3M
- Earning Date
- KFS 05-08-2025
- TNXP 05-12-2025
- Dividend Yield
- KFS N/A
- TNXP N/A
- EPS Growth
- KFS N/A
- TNXP N/A
- EPS
- KFS N/A
- TNXP N/A
- Revenue
- KFS $114,710,000.00
- TNXP $10,041,000.00
- Revenue This Year
- KFS N/A
- TNXP $12.17
- Revenue Next Year
- KFS N/A
- TNXP $789.15
- P/E Ratio
- KFS N/A
- TNXP N/A
- Revenue Growth
- KFS 6.75
- TNXP N/A
- 52 Week Low
- KFS $7.06
- TNXP $6.76
- 52 Week High
- KFS $13.58
- TNXP $558.08
- Technical
- Relative Strength Index (RSI)
- KFS 86.65
- TNXP 74.56
- Support Level
- KFS $10.03
- TNXP $25.40
- Resistance Level
- KFS $13.58
- TNXP $37.84
- Average True Range (ATR)
- KFS 0.69
- TNXP 4.17
- MACD
- KFS 0.26
- TNXP 1.75
- Stochastic Oscillator
- KFS 84.71
- TNXP 87.00
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.